# AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

> **NCT02388295** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 59 (actual)

## Conditions studied

- Multiple System Atrophy, MSA

## Interventions

- **DRUG:** AZD3241
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02388295
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-27
- **Primary completion:** 2016-09-19
- **Final completion:** 2016-09-19
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2017-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02388295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02388295, "AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02388295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*